Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 01 04:00PM ET
3.20
Dollar change
+0.01
Percentage change
0.31
%
Index- P/E- EPS (ttm)-1.23 Insider Own4.15% Shs Outstand36.82M Perf Week2.56%
Market Cap118.19M Forward P/E- EPS next Y-1.41 Insider Trans0.00% Shs Float35.29M Perf Month-19.19%
Income-40.68M PEG- EPS next Q-0.30 Inst Own14.49% Short Float13.60% Perf Quarter1.59%
Sales0.00M P/S- EPS this Y12.95% Inst Trans-26.21% Short Ratio15.58 Perf Half Y-16.23%
Book/sh0.84 P/B3.81 EPS next Y-16.80% ROA-65.48% Short Interest4.80M Perf Year-23.44%
Cash/sh1.56 P/C2.05 EPS next 5Y- ROE-128.40% 52W Range2.53 - 6.85 Perf YTD-35.61%
Dividend Est.- P/FCF- EPS past 5Y42.97% ROI-90.76% 52W High-53.28% Beta1.93
Dividend TTM- Quick Ratio3.84 Sales past 5Y0.00% Gross Margin- 52W Low26.48% ATR (14)0.24
Dividend Ex-Date- Current Ratio3.84 EPS Y/Y TTM24.20% Oper. Margin0.00% RSI (14)47.46 Volatility8.14% 6.72%
Employees25 Debt/Eq0.79 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price12.40
Option/ShortYes / Yes LT Debt/Eq0.45 EPS Q/Q39.39% Payout- Rel Volume0.81 Prev Close3.19
Sales Surprise- EPS Surprise29.60% Sales Q/Q- EarningsAug 13 BMO Avg Volume308.05K Price3.20
SMA20-1.99% SMA50-1.37% SMA200-14.99% Trades Volume250,081 Change0.31%
Date Action Analyst Rating Change Price Target Change
Nov-01-22Initiated B. Riley Securities Buy $10
Jun-28-21Initiated Cantor Fitzgerald Overweight $25
Nov-10-20Upgrade H.C. Wainwright Neutral → Buy $6
May-27-20Initiated Alliance Global Partners Buy $4
Mar-09-20Initiated Noble Capital Markets Outperform $5.45
Oct-24-19Initiated Chardan Capital Markets Buy $10
Oct-22-24 12:00PM
08:00AM
Oct-02-24 08:00AM
Sep-16-24 07:00AM
Sep-09-24 08:00AM
08:00AM Loading…
Sep-03-24 08:00AM
Aug-13-24 08:09AM
08:00AM
Aug-08-24 08:00AM
Aug-07-24 08:00AM
Aug-05-24 08:00AM
Aug-01-24 07:45AM
Jul-31-24 04:01PM
Jul-29-24 08:00AM
Jun-12-24 08:00AM
01:24PM Loading…
May-28-24 01:24PM
May-15-24 12:52PM
08:08AM
08:00AM
May-10-24 05:49AM
May-09-24 05:46PM
08:00AM
May-07-24 08:00AM
May-03-24 08:00AM
May-02-24 08:00AM
Apr-23-24 08:00AM
Mar-28-24 10:24AM
Mar-27-24 11:33PM
11:52AM
08:51AM
07:30AM Loading…
07:30AM
Mar-20-24 08:00AM
Mar-13-24 10:55AM
08:00AM
Jan-22-24 04:45PM
Jan-16-24 08:00AM
Jan-02-24 12:00PM
Dec-04-23 04:50PM
Nov-28-23 07:30AM
Nov-15-23 01:03PM
Nov-14-23 12:19PM
07:42AM
07:30AM
Nov-09-23 08:00AM
Nov-07-23 08:00AM
Oct-23-23 08:00AM
Oct-11-23 08:00AM
Oct-03-23 07:00AM
Oct-02-23 08:00AM
Sep-26-23 08:00AM
Sep-25-23 08:00AM
Sep-20-23 04:05PM
08:00AM
Sep-13-23 08:00AM
Sep-06-23 04:05PM
08:00AM
Aug-29-23 11:32AM
Aug-16-23 08:00AM
Aug-14-23 11:42PM
07:37AM
07:30AM
07:00AM
Aug-07-23 08:00AM
Aug-02-23 08:00AM
Jul-25-23 08:00AM
Jul-17-23 08:00AM
Jul-11-23 08:00AM
Jun-30-23 04:05PM
Jun-20-23 08:00AM
Jun-14-23 08:00AM
Jun-05-23 02:52PM
May-25-23 05:00PM
May-18-23 08:00AM
May-17-23 01:54PM
May-15-23 09:46PM
07:40AM
07:30AM
May-04-23 08:00AM
Apr-27-23 08:00AM
Apr-24-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 08:28AM
08:00AM
Mar-29-23 07:30AM
Mar-28-23 07:30AM
Mar-16-23 08:00AM
Mar-07-23 08:00AM
Mar-01-23 08:00AM
Feb-27-23 08:00AM
Feb-16-23 08:00AM
Feb-15-23 09:00AM
Feb-08-23 04:00PM
Feb-06-23 08:00AM
Jan-26-23 08:00AM
Jan-13-23 08:00AM
Jan-03-23 11:13AM
07:00AM
Dec-29-22 10:29AM
Dec-28-22 10:39AM
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.